{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:33:53Z","timestamp":1790249633926,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039192"],"award-info":[{"award-number":["R01DA039192"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG024832"],"award-info":[{"award-number":["P30AG024832"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,12,13]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Examine the association between the co-prescribing of opioids, benzodiazepines, gabapentinoids (pregabalin and gabapentin) and selective serotonin reuptake inhibitors\/serotonin and norepinephrine reuptake inhibitors (SSRI\/SNRIs) in different combinations and the risk of falls and fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study from 2015 to 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Medicare enrolment and claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Medicare beneficiaries with both chronic pain and anxiety disorders in 2016 with continuous enrolments in Parts A and B from 2015 to 2016 who were prescribed any combination of opioid, benzodiazepine, gabapentinoid and SSRI\/SNRI in 2017 for \u22657\u2009days, as documented in their Medicare Part D coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Any combination of use of seven drug regimens (benzodiazepine +opioid; benzodiazepine +gabapentinoid; benzodiazepine +SSRI\/SNRI; opioid +gabapentinoid; opioid +SSRI\/SNRI; gabapentinoid +SSRI\/SNRI; \u22653\u2009drug classes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes<\/jats:title>\n                    <jats:p>First event of fall and the first event of fracture after the index date, which was the first day of combination drug use that lasted \u22657\u2009days in 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47\u2009964 patients (mean [SD] age, 75.9 [7.1]; 78.0% woman) with diagnoses of both chronic pain and anxiety were studied. The median (Q1\u2013Q3) duration of drug combination use was 26 (14-30) days. After adjusting for demographic characteristics, chronic conditions and history of hospitalisation and fall or fracture, the co-prescribing of \u22653 drugs (adjusted HR [aHR], 1.38; 95%\u2009CI 1.14 to 1.67) and opioid plus gabapentinoid (aHR, 1.18; 95%\u2009CI 1.02 to 1.37) were associated with a high fall risk, compared with benzodiazepineplus opioid co-prescribing, findings consistent with the secondary analysis using inverse probability of treatment weighting with propensity scores. The co-prescribing of benzodiazepine plus gabapentinoid (aHR, 0.76; 95%\u2009CI 0.59 to 0.98) was associated with lower fracture risk compared with the co-prescribing of benzodiazepine plus opioid, though this finding was not robust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings add to comparative toxicity research on different combinations of gabapentinoids and serotonergic agents commonly prescribed with or as substitutes for opioids and benzodiazepines in patients with co-occurring chronic pain and anxiety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-052057","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T22:42:51Z","timestamp":1640904171000},"page":"e052057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Association of co-prescribing of opioid and benzodiazepine substitutes with incident falls and fractures among older adults: a cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-4690","authenticated-orcid":false,"given":"Rahul","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-7281","authenticated-orcid":false,"given":"Mukaila A","family":"Raji","sequence":"additional","affiliation":[{"name":"Division of Geriatrics and Palliative Medicine, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"},{"name":"Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Westra","sequence":"additional","affiliation":[{"name":"Office of Biostatistics, Department of Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"},{"name":"Department of Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"2025120519514946000_11.12.e052057.1","doi-asserted-by":"crossref","unstructured":"Wilson N . Drug and Opioid-Involved overdose deaths \u2014 United States, 2017\u20132018. MMWR Morb Mortal Wkly Rep 2020;69.","DOI":"10.15585\/mmwr.mm6911a4"},{"key":"2025120519514946000_11.12.e052057.2","unstructured":"Understanding the Epidemic . Drug overdose | CDC injury center 2020."},{"key":"2025120519514946000_11.12.e052057.3","unstructured":"CDC . Annual surveillance report of drug-related risks and outcomes, 2019."},{"key":"2025120519514946000_11.12.e052057.4","doi-asserted-by":"crossref","unstructured":"Gladden RM . Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine \u2014 25 states, July\u2013December 2017 to January\u2013June 2018. MMWR Morb Mortal Wkly Rep 2019:68.","DOI":"10.15585\/mmwr.mm6834a2"},{"key":"2025120519514946000_11.12.e052057.5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Med"},{"key":"2025120519514946000_11.12.e052057.6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1472767"},{"key":"2025120519514946000_11.12.e052057.7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pmedr.2017.12.010","article-title":"Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014","volume":"9","author":"Hirschtritt","year":"2018","journal-title":"Prev Med Rep"},{"key":"2025120519514946000_11.12.e052057.8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/gerona\/gly283","article-title":"Coprescribing of benzodiazepines and opioids in older adults: rates, correlates, and national trends","volume":"74","author":"Rhee","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025120519514946000_11.12.e052057.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"2025120519514946000_11.12.e052057.10","doi-asserted-by":"publisher","DOI":"10.1002\/da.20600"},{"key":"2025120519514946000_11.12.e052057.11","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2019.12.09"},{"key":"2025120519514946000_11.12.e052057.12","doi-asserted-by":"publisher","DOI":"10.1177\/0897190013515001"},{"key":"2025120519514946000_11.12.e052057.13","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs178"},{"key":"2025120519514946000_11.12.e052057.14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/pop.2019.0128","article-title":"Concurrent use of opioids with other central nervous System-Active medications among older adults","volume":"23","author":"Musich","year":"2020","journal-title":"Popul Health Manag"},{"key":"2025120519514946000_11.12.e052057.15","doi-asserted-by":"crossref","unstructured":"CDC guideline for prescribing opioids for chronic pain \u2014 United States, 2016. MMWR Recomm Rep 2016;65.","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"2025120519514946000_11.12.e052057.16","unstructured":"U.S. Food and Drug Administration . FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Drug safety communications, 2017. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or [Accessed 5 Oct 2020]."},{"key":"2025120519514946000_11.12.e052057.17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8325","article-title":"Rates of physician coprescribing of opioids and benzodiazepines after the release of the centers for disease control and prevention guidelines in 2016","volume":"2","author":"Jeffery","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025120519514946000_11.12.e052057.18","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1243"},{"key":"2025120519514946000_11.12.e052057.19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025120519514946000_11.12.e052057.20","first-page":"672","article-title":"Gabapentinoids for pain: potential unintended consequences","volume":"100","author":"Goodman","year":"2019","journal-title":"Am Fam Physician"},{"key":"2025120519514946000_11.12.e052057.21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025120519514946000_11.12.e052057.22","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"key":"2025120519514946000_11.12.e052057.23","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f0f0d7"},{"key":"2025120519514946000_11.12.e052057.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2251-x"},{"key":"2025120519514946000_11.12.e052057.25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jgs.15779","article-title":"Tricyclic antidepressant and\/or \u03b3-aminobutyric Acid-Analog use is associated with fall risk in diabetic peripheral neuropathy","volume":"67","author":"Randolph","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2025120519514946000_11.12.e052057.26","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1136"},{"key":"2025120519514946000_11.12.e052057.27","article-title":"Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives","volume":"61","author":"Longo","year":"2000","journal-title":"Am Fam Physician"},{"key":"2025120519514946000_11.12.e052057.28","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1472767"},{"key":"2025120519514946000_11.12.e052057.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31793-8"},{"key":"2025120519514946000_11.12.e052057.30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00307"},{"key":"2025120519514946000_11.12.e052057.31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","article-title":"Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights","volume":"338","author":"Kremer","year":"2016","journal-title":"Neuroscience"},{"key":"2025120519514946000_11.12.e052057.32","unstructured":"Centers for medicare & medicaid services chronic condition data warehouse: chronic condition categories. Available: https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories [Accessed 1 Mar 2020]."},{"key":"2025120519514946000_11.12.e052057.33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamainternmed.2016.9225","article-title":"Trends in central nervous system-active polypharmacy among older adults seen in outpatient care in the United States","volume":"177","author":"Maust","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2025120519514946000_11.12.e052057.34","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1111\/jgs.16212","article-title":"Polypharmacy and incident frailty in a longitudinal community-based cohort study","volume":"67","author":"Shmuel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2025120519514946000_11.12.e052057.35","doi-asserted-by":"crossref","unstructured":"Borda MG , Jaramillo-Jimenez A , Oesterhus R . Benzodiazepines and antidepressants: effects on cognitive and functional decline in Alzheimer\u2019s disease and Lewy body dementia [published online ahead of print, 2020 Dec 31]. Int J Geriatr Psychiatry. 2020.","DOI":"10.1002\/gps.5494"},{"key":"2025120519514946000_11.12.e052057.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698"},{"key":"2025120519514946000_11.12.e052057.37","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1218-z"},{"key":"2025120519514946000_11.12.e052057.38","doi-asserted-by":"crossref","first-page":"1414.e7","DOI":"10.1016\/j.amjmed.2005.07.033","article-title":"Bone mineral density in subjects using central nervous system-active medications","volume":"118","author":"Kinjo","year":"2005","journal-title":"Am J Med"},{"key":"2025120519514946000_11.12.e052057.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220216","article-title":"An updated analysis of opioids increasing the risk of fractures","volume":"15","author":"Yue","year":"2020","journal-title":"PLoS One"},{"key":"2025120519514946000_11.12.e052057.40","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00006"},{"key":"2025120519514946000_11.12.e052057.41","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"key":"2025120519514946000_11.12.e052057.42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-052057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:52:02Z","timestamp":1764993122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-052057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,30]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjopen-2021-052057"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-052057","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}